Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Recent Scientific Advances in Vaccines for Shigella
share announcement

Recent Scientific Advances in Vaccines for Shigella

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 2032

Special Issue Editors

Dr. Akamol Suvarnapunya

E-Mail
Guest Editor
Center for Infectious Disease Research, Bacterial Diseases Branch, Department of Diarrheal Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA
Interests: shigella; salmonella; diarrhea; enteric disease; enteric vaccines; global health
Dr. Kristen A Clarkson

E-Mail
Guest Editor
Center for Infectious Disease Research, Bacterial Diseases Branch, Department of Diarrheal Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA
Interests: vaccines; immunology; enterics; B cells; global health; correlates of protection
Dr. Renee Laird

E-Mail
Guest Editor
Center for Infectious Disease Research, Bacterial Diseases Branch, Department of Diarrheal Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA
Interests: enteric; vaccines; immunology; antibodies; T cells; B cells
Dr. August Louis Bourgeois

E-Mail
Guest Editor
Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Interests: global health; enteric disease epidemiology; enteric vaccines; mucosal immunity; vaccine adjuvants; vaccine delivery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Diarrheal disease is a major global health problem, especially for children in low- to middle-income countries. Shigella is the leading etiology of diarrhea-associated mortality in children under 5 years of age and the second-leading etiology of diarrhea-associated mortality across all age groups. Shigella is also an important cause of Traveler’s diarrhea and has been associated with several post-infectious sequelae such as reactive arthritis and irritable bowel syndrome (IBS).

Antibiotic treatment is commonly prescribed for shigellosis, but the global spread of antimicrobial-resistant (AMR) Shigella strains threatens this treatment option. Accordingly, the World Health Organization (WHO) has designated Shigella spp. as Priority Pathogens for the development of new therapeutics or preventive measures. The development of an effective vaccine against Shigella represents the ideal solution to the intertwined global health issues of shigellosis and the rise in AMR Shigella.

A variety of Shigella vaccine candidates are in clinical testing, including conjugate vaccines, outer membrane vesicles, recombinant subunit vaccines, and live attenuated vaccines. In addition, the preclinical pipeline contains several more vaccine candidates, including killed whole-cell vaccines and multi-pathogen (combination) vaccines. This Special Issue will feature the latest advances in the Shigella vaccine field. We invite contributions regarding preclinical vaccine development and clinical findings, as well as assay development for the evaluation of vaccine immunogenicity and potential correlates of protection.

Dr. Akamol E. Suvarnapunya
Dr. Kristen A Clarkson
Dr. Renee M. Laird
Dr. August Louis Bourgeois
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Shigella
  • vaccines
  • global health

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

13 pages, 227 KiB  
Article
A Candidate Ac3-S-LPS Vaccine Against S. flexneri 1b, 2a, 3a, 6, and Y Activates Long-Lived Systemic and Mucosal Immune Responses in Healthy Volunteers: Results of an Open-Label, Randomized Phase 2 Clinical Trial
by Vladimir A. Ledov, Victor V. Romanenko, Marina E. Golovina, Biana I. Alkhazova, Alexander L. Kovalchuk and Petr G. Aparin
Vaccines 2025, 13(3), 209; https://doi.org/10.3390/vaccines13030209 - 20 Feb 2025
Viewed by 370
Abstract
Objectives: Determination of reactogenicity and immunogenicity of a pentavalent candidate vaccine against S. flexneri 1b, 2a, 3a, 6, and Y (PLVF). Methods: The study involved 80 healthy adult volunteers aged 18–55 years. Groups were subcutaneously immunized twice at a 30-day interval with 62.5 [...] Read more.
Objectives: Determination of reactogenicity and immunogenicity of a pentavalent candidate vaccine against S. flexneri 1b, 2a, 3a, 6, and Y (PLVF). Methods: The study involved 80 healthy adult volunteers aged 18–55 years. Groups were subcutaneously immunized twice at a 30-day interval with 62.5 μg/0.5 mL or 125 μg/0.5 mL of the vaccine. Results: During the entire 8-month period of post-vaccination observation, the vaccine was well tolerated, with no local or systemic reactions detected objectively. The results of laboratory studies demonstrated no effect on the main indicators of hemogram, biochemical blood test, or urinalysis. IgA, IgG, and IgM levels against LPS S. flexneri 1b, 2a, 3a, 6, and Y were examined before vaccination, a month after each vaccination, and 6 months after booster vaccination. One month after vaccination, IgA and IgG seroconversions were observed in 67.5–82.5% (depending on serotype) and 60–77.5% of volunteers, respectively. Booster immunization did not have a significant effect on vaccine immunogenicity. In two separate groups of 15 and 9 volunteers for mucosal sIgA, IgA, and IgG titer determination after immunization with a 125 μg vaccine dose, paired stool, and saliva samples were taken before and one month after vaccination. In 26.7–40% of volunteers, there was a 2-fold and higher increase in sIgA titer for the studied serotypes in the feces and in 66.7–88.9% in saliva. IgA and IgG 2-fold conversion rates were 26.7–53.3% and 33.3–46.7% in the feces, 33.3–77.9%, and 66.7–77.8% in saliva, respectively. Conclusions: the tolerability of PLVF and the pronounced humoral immune response allow us to proceed to the phase 3 clinical trial stage. Full article
(This article belongs to the Special Issue Recent Scientific Advances in Vaccines for Shigella)

Other

Jump to: Research

12 pages, 517 KiB  
Study Protocol
Safety, Tolerability, and Immunogenicity of the InvaplexAR-Detox Shigella Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial
by Geert V. T. Roozen, Nsofwa Sukwa, Masuzyo Chirwa, Jessica A. White, Marcus Estrada, Nicole Maier, Kevin R. Turbyfill, Renee M. Laird, Akamol E. Suvarnapunya, Aicha Sayeh, Flavia D’Alessio, Candice Marion, Laura Pattacini, Marie-Astrid Hoogerwerf, Rajagopal Murugan, Manuela Terrinoni, Jan R. Holmgren, Sodiomon B. Sirima, Sophie Houard, Michelo Simuyandi and Meta Roestenbergadd Show full author list remove Hide full author list
Vaccines 2025, 13(1), 48; https://doi.org/10.3390/vaccines13010048 - 8 Jan 2025
Cited by 1 | Viewed by 1150
Abstract
Background: Shigella infections remain endemic in places with poor sanitation and are a leading cause of diarrheal mortality globally, as well as a major contributor to gut enteropathy and stunting. There are currently no licensed vaccines for shigellosis but it has been estimated [...] Read more.
Background: Shigella infections remain endemic in places with poor sanitation and are a leading cause of diarrheal mortality globally, as well as a major contributor to gut enteropathy and stunting. There are currently no licensed vaccines for shigellosis but it has been estimated that an effective vaccine could avert 590,000 deaths over a 20-year period. A challenge to effective Shigella vaccine development has been the low immunogenicity and protective efficacy of candidate Shigella vaccines in infants and young children. Additionally, a new vaccine might be less immunogenic in a highly endemic setting compared to a low endemic setting (“vaccine hyporesponsiveness”). The use of a potent adjuvant enhancing both mucosal and systemic immunity might overcome these problems. InvaplexAR-Detox is an injectable Shigella vaccine that uses a novel combination of conserved invasion plasmid antigen proteins and a serotype-specific bacterial lipopolysaccharide attenuated for safe intramuscular administration. The adjuvant dmLT has been shown to enhance Shigella immune responses in mice, has safely been administered intramuscularly, and was shown to enhance immune responses in healthy volunteers when given in combination with other antigens in phase I trials. This article describes the protocol of a study that will be the first to assess the safety, tolerability, and immunogenicity of InvaplexAR-Detox co-administered with dmLT in healthy adults in low-endemic and high-endemic settings. Methods: In a multi-center, randomized, double-blind, and placebo-controlled dose-escalation phase Ia/b trial, the safety, tolerability, and immunogenicity of three intramuscular vaccinations administered 4 weeks apart with 2.5 µg or 10 µg of InvaplexAR-Detox vaccine, alone or in combination with 0.1 µg of the dmLT adjuvant, will first be assessed in a total of 50 healthy Dutch adults (phase Ia) and subsequently in 35 healthy Zambian adults (phase Ib) aged 18–50 years. The primary outcome is safety, and secondary outcomes are humoral and cellular immune responses to the adjuvanted or non-adjuvanted vaccine. Discussion: This trial is part of the ShigaPlexIM project that aims to advance the early clinical development of an injectable Shigella vaccine and to make the vaccine available for late-stage clinical development. This trial addresses the issue of hyporesponsiveness in an early stage of clinical development by testing the vaccine and adjuvant in an endemic setting (Zambia) after the first-in-human administration and the dose-escalation has proven safe and tolerable in a low-endemic setting (Netherlands). Besides strengthening the vaccine pipeline against a major diarrheal disease, another goal of the ShigaPlexIM project is to stimulate capacity building and strengthen global North-South relations in clinical research. Trial registration: EU CT number: 2023-506394-35-02, ClinicalTrials.gov identifier: NCT05961059. Full article
(This article belongs to the Special Issue Recent Scientific Advances in Vaccines for Shigella)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop